Skip to main content
OpenTrials

Clinical trial condition

Lung Neoplasms

Explore clinical trials studying Lung Neoplasms. Study availability and eligibility vary by location and protocol.

4,207 public trials 1,003 recruiting studies
Refine in advanced search Browse all conditions

Lung Neoplasms trial results

Active, Not Recruiting

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Limited-Stage Small Cell Lung Cancer, +8 more
Locations
  • OPN-Glendale Arcadia, California, United States
  • OPN-Los Alamitos Los Alamitos, California, United States
  • Southern California Permanente Group Los Angeles, California, United States
  • Emad Ibrahim, MD, Inc Redlands, California, United States
View all 129 locations
View Trial Details
Active, Not Recruiting

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

NCT05074810

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Rocky Mountain Cancer Center, LLP Boulder, Colorado, United States
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • MedStar Washington Hospital Center, MedStar Georgetown Cancer Institute, Washington D.C., District of Columbia, United States
  • Illinois Cancer Specialists Arlington Heights, Illinois, United States
View all 35 locations
View Trial Details
Active, Not Recruiting

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

NCT02988960

Conditions
Advanced Solid Tumors Cancer, Bronchial Neoplasms, Carcinoma, +23 more
Locations
  • The Angeles Clinic and Researc /ID# 156324 Los Angeles, California, United States
  • The University of Chicago Medical Center /ID# 155264 Chicago, Illinois, United States
  • Massachusetts General Hospital /ID# 155267 Boston, Massachusetts, United States
  • Carolina BioOncology Institute /ID# 155265 Huntersville, North Carolina, United States
View all 22 locations
View Trial Details
Active, Not Recruiting

A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

NCT03782207

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +22 more
Locations
  • Hospital Universitario Austral Buenos Aires, Argentina
  • Lucen S.A. Buenos Aires, Argentina
  • Consultorio Privado Korbenfeld CABA, Argentina
  • Hospital Italiano de Buenos Aires Ciudad Autonoma Buenos Aires, Argentina
View all 258 locations
View Trial Details
Active, Not Recruiting

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Beverly Hills Cancer Center Beverly Hills, California, United States
  • The Oncology Institute of Hope and Innovation Glendale, California, United States
  • Moores Cancer Center at UC San Diego La Jolla, California, United States
  • Keck Medicine of University of Southern California Los Angeles, California, United States
View all 77 locations
View Trial Details
Active, Not Recruiting

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, +8 more
Locations
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Oncology and Hematology Anchorage, Alaska, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • University of California Los Angeles Santa Monica, California, United States
View all 223 locations
View Trial Details
Active, Not Recruiting

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

NCT05609968

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Infirmary Cancer Care ( Site 0418) Mobile, Alabama, United States
  • Profound Research LLC ( Site 0444) Oceanside, California, United States
  • Clermont Oncology Center ( Site 0421) Clermont, Florida, United States
  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0417) Miami, Florida, United States
View all 180 locations
View Trial Details

Related conditions